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months pre- and post-index periods. Patients with diabetic peripheral neuropathic pain 
(DPNP) or depression in the 12 months pre-index period were excluded. Each patient 
was classiﬁed in the duloxetine or prebagalin cohort based on the initial agent. Pre-
bagalin cohort was constructed via propensity scoring controlling for differences in 
demographics, pre-index clinical and economic characteristics, and pre-index treat-
ment patterns. Medication compliance (i.e. medication possession ratio (MPR) and 
proportion of patients with MPRq80%) and health care costs over the 12 months 
post-index period were examined between cohorts. RESULTS: Both the duloxetine (n 
 3711) and pregabalin (n  4111) cohorts had the mean age around 50 years. Many 
duloxetine and pregabalin patients had neuropathic pain other than DPNP (69.1% 
vs. 69.1%), low back pain (61.9% vs. 62.1%), cardiovascular disease (55.1% vs. 
55.1%), hypertension (44.9% vs. 45.0%), and headache (36.0% vs. 35.3%), and used 
opioids (75% vs. 86%). Controlling for demographics, pre-index clinical and eco-
nomic characteristics, and prior medication history, duloxetine patients had signiﬁ-
cantly higher MPR (0.66 vs. 0.50, p  0.05), higher proportion of patients with 
MPRq80% (47% vs. 26%, p  0.05), and signiﬁcantly lower total health care costs 
($19,378 vs. $27,045, p  0.05) over the 12 months follow-up period than pregabalin 
patients. CONCLUSIONS: Fibromyalgia patients treated with duloxetine had signiﬁ-
cantly higher medication compliance, but signiﬁcantly lower direct health care costs 
than those on pregabalin.
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OBJECTIVES: To describe the adherence for different treatment regimens of oral 
bisphosphonates (oBP) in osteoporosis patients in Germany. METHODS: Analyses 
used IMS® Disease Analyser database (contains representative information on 
approximately 11 million patients from ofﬁce-based physicians). Osteoporosis patients 
with a history of malignant diseases, any anticancer or cytostatic hormone prescrip-
tions, Paget’s disease or AIDS were excluded. Eligible osteoporosis patients had data 
available at least 1-year before and after starting oBP treatment between Dec 2004 
and Nov 2007. Compliance was measured as Medical Possession Ratio (MPR); 
deﬁned as the ratio of prescribed to assumed number of therapy units. MPR  80% 
assumed compliance. MPR was calculated for patients on therapy for a maximum of 
2 years. RESULTS: Data from 4,738 patients were analyzed: 4147 (87.5%) women, 
4130 (87.2%) older than 60 years. A total of 177 (3.7%) received daily, 4367 (92.2%) 
weekly and 194 (4.1%) monthly oBP treatment. The mean MPR was 0.66 (daily), 
0.83 (weekly) and 0.84 (monthly) in the oBP treatment period. In total, only 51% of 
patients had an MPR  80%. Overall, 72% patients discontinued/switched oBP 
regimen during the ﬁrst year: 90.4% (daily), 71.6% (weekly) and 70.6% (monthly). 
CONCLUSIONS: The majority of patients were receiving weekly oBP therapy. Com-
pliance varied for the different treatment regimens, but was particularly poor in 
patients receiving daily oBP treatment. In addition, a high proportion of patients dis-
continued/switched oBP regimens during the ﬁrst year. This study provides further 
evidence of poor adherence in patients with osteoporosis receiving oBP therapy.
PMS69
ITEM REDUCTION AND VALIDATION OF A NEW ADHERENCE 
QUESTIONNAIRE IN OSTEOPOROTIC POST-MENOPAUSAL WOMEN: 
THE ADHERENCE EVALUATION OF OSTEOPOROSIS TREATMENT 
(ADEOS) QUESTIONNAIRE
Cortet B1, Legrand E2, Breuil V3, Regnault A4, Dias-Barbosa C4, Roborel de Climens A5, 
Gaudin AF6, Cotte FE6
1CHRU Lille, Lille, France, 2CHU, Angers, France, 3CHU de Nice, Nice, France, 4Mapi Values 
France, Lyon, France, 5Mapi Values, Lyon, France, 6GlaxoSmithKline France, Marly le Roi, 
France
OBJECTIVES: To reduce and validate the ADEOS questionnaire, an instrument spe-
ciﬁcally developed to evaluate treatment adherence by women with post-menopausal 
osteoporosis. METHODS: The ADEOS questionnaire has been developed with clini-
cians and patients. Before item reduction, it included 45 items covering 5 distinct 
themes related to adherence (personal characteristics, beliefs, perceptions, behaviour 
and information received). It was included for ﬁnalisation and validation in a cross-
sectional observational study in French general practitioners. The study sample was 
randomly divided into 2 subsamples: one for item selection, one for validation. The 
item selection procedure was performed according to the association of the items with 
a generic measure of compliance, the Morisky Medication Adherence Scale (MMAS). 
The validity of the score derived from these items was scrutinised by assessing its 
correlation with MMAS score. Its ability to separate compliant patients from non 
compliant patients according to MMAS was studied using area under receiver-operat-
ing characteristic curve (AUC). RESULTS: Five hundred sixty osteoporotic women 
were included, of whom 348 (62%) returned the ADEOS questionnaire. Patients who 
did not return the questionnaire were comparable to those who did in terms of demo-
graphics and medical parameters. The questionnaire quality of completion was very 
good, conﬁrming its good acceptability. Twelve items of the questionnaire showed a 
statistically signiﬁcant relationship (p  0.05) with the MMAS in the “item selection 
sample” (N  200) and were retained to derive the ADEOS score. In the “validation 
sample” (N  148), the ADEOS score was noticeably correlated with MMAS score 
(Spearman correlation coefﬁcient: 0.58) and showed good discriminant validity 
according to MMAS (AUC: 0.84). CONCLUSIONS: The 12-item ADEOS question-
naire is a short validated instrument speciﬁc to osteoporosis, whose score can easily 
be calculated by hand. Therefore, it might be particularly useful in daily practice to 
detect patients at risk of being poorly adherent to their osteoporosis treatment.
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OBJECTIVES: Recent anti-osteoporotic treatments are characterised by monthly or 
even yearly administration. These treatments may challenge the prescription of daily-
administered drugs. The objective of this qualitative research was to explore patients’ 
perception as well as clinicians’ views on the frequency of anti-osteoporotic treatment 
administration. METHODS: A health psychologist carried out face-to-face interviews 
with six patients treated on a daily basis and six patients treated with a monthly-
administered drug. The patients’ perception, behaviour and expectations regarding 
anti-osteoporotic treatment were assessed. Clinicians who recruited the patients, com-
prising a general practitioner and specialists, were also interviewed. Information on 
factors driving their treatment choice decision and on the importance of patients’ 
feedback and perception in their decision was collected. RESULTS: Patients perceived 
osteoporosis as a sign of premature ageing and a disease of secondary importance. 
They reported that a daily administration was not a problem per se if it did not modify 
their lifestyle. They raised concerns about lower frequency of drug administration that 
clinicians did not: the difﬁculty of remembering to take the treatment; the worry about 
the treatment being too concentrated, with the thought of a possible irregular efﬁcacy 
of the drug over the time and a harmful effect. They did not feel involved in the choice 
of treatment. Clinicians believed monthly administration to be more convenient than 
daily administration. They declared choosing the treatment according to the patient’s 
characteristics, in particular concomitant diseases, lifestyle, and dosing preference. 
CONCLUSIONS: Discrepancies exist between clinicians’ perception and reality for 
patients regarding anti-osteoporotic treatment. Consequently, possible patient-
reported outcomes approaches to improve treatment-decision would consist in 1) 
educating patients on osteoporosis, and clinicians on their patients’ perception and 
expectations, and 2) promoting shared decision-making. This is likely to contribute 
to a better persistence of the patients with regard to their treatment.
PMS71
PREDICTING CHANGES IN EQ-5D UTILITY SCORE VIA PASI OR HAQ IN 
PSORIATIC ARTHRITIS PATIENTS
Zbrozek A1, Kirkham B2, Li W1, Molta C1, Singh A1
1Wyeth Research, Philadelphia, PA, USA, 2University of New South Wales, Sydney, NSW, 
Australia
OBJECTIVES: To compare the predictive power post hoc of skin signs and physical 
function in improvement of health state utility scores in a population with active 
psoriatic arthritis (PsA). METHODS: A 12-week randomized double-blind study fol-
lowed by a 12-week open-label extension; subjects received etanercept 50 mg BIW or 
50 mg QW during the double-blind period followed by 50 mg QW during the open-
label period. Eligibility criteria included: age 18 y; stable, moderate-to-severe plaque 
psoriasis with q2 swollen/painful joints. PASI for psoriasis signs, HAQ for physical 
function, and EQ-5D were measured at baseline, Weeks 12 and 24. Logistic regression 
was used to predict the minimally clinically meaningful change in EQ-5D of at least 
0.05 (0–1.0 scale). Meaningful changes from baseline as predictors: HAQ  0.375, 
0.5; PASI  50%, 75%. RESULTS: At baseline, subjects (n  752) had a mean age 
47 y, were 63% male, and 89% white. Mean number of tender joints 19.2, and 
swollen joints 12.5. Mean durations of psoriasis and psoriatic arthritis 19 and 7 
years, respectively. Baseline scores were not signiﬁcantly different between the 2 
groups; pooled baseline (mean o s.d.) PASI  19.43 o 10.28, HAQ  0.91 o 0.69, and 
EQ-5D  0.48 o 0.32. Only PASI change from baseline at Week 12 differentiated 
treatment groups. Pooled reductions from baseline to Week 24 (LOCF) were: PASI  
75.9%, HAQ  52.0%. Proportion achieving EQ-5D (q0.05)  74.6%. HAQ changes 
from baseline were stronger predictors of pre-determined changes in EQ-5D utility 
scores than PASI changes, with HAQ change q0.375 at Week 24 being the strongest 
single change predictor (OR  4.36 (2.01–9.44)). Higher baseline HAQ scores reduced 
the odds 0.12 (0.07–0.20), and 0.19 (0.11–0.31) for minimally meaningful health 
status improvements at Weeks 12 and 24, respectively. CONCLUSIONS: Patients 
with less advanced PsA could have better odds of meaningful improvement in health 
status when treated to reduce both skin and joint morbidity.
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OBJECTIVES: To examine the relationship between disease speciﬁc-measure, Health 
Assessment Questionnaire (HAQ) disability index (DI) and the preference-based mea-
sures, Short Form-6D (SF-6D) and the EuroQoL (EQ-5D) in patients with rheumatoid 
arthritis(RA) and psoriatic arthritis (PsA). METHODS: Five hundred and four patients 
attending a rheumatology outpatient clinic with RA and PsA completed the HAQ, 
Short Form-36 and the EQ-5D before starting biologic therapy and 12 months after. 
